CliffBio
small molecule

FULVESTRANT

FULVESTRANT

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameFULVESTRANT
Active ingredientFULVESTRANT
Strength250MG/5ML (50MG/ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJune 2021
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.